Dorothy Engelking

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Kendle International LLC provides research and development services to biopharmaceutical companies by offering value-added clinical research services and proprietary information technology. The company was founded in 1981 and is headquartered in Cincinnati, OH.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management and women's healthcare. It markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins. The firm's product candidates include XP12B, a tranexamic acid modified release oral tablet for the reduction of menstrual blood loss in women, who suffer from menorrhagia or excessive menstrual bleeding; and XP20B is a combination propoxyphene and acetaminophen modified release oral tablet for the treatment of mild to moderate pain. The company was founded by Gilbert R. Gonzales and Roger Dale Griggs in May 2001 and is headquartered in Newport, KY.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.